Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.
TrakCel, a provider of cellular orchestration systems to the cell and gene therapy (CGT) industry, has launched its own consultancy services to share its process development knowledge with the broader community of CGT developers.
Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US.
Pharma giant, GSK, plans to invest £200 million ($253 million) into the UK over the next two years and has acquired Aiolos Bio for $1.1 billion (£870 million).
CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of novel cell therapies, has announced a £7.6 million seed round.
Sexual health pharmaceutical company Futura Medical has extended its exclusive licensing agreement with Cooper Consumer Health for the rights to commercialize its topical, gel-based erectile dysfunction treatment.
Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view:
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to...
Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.
Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.
A £30 million ($38 million) study into liver cirrhosis, the most extensive ever conducted worldwide has been announced by Newcastle University and University of Edinburgh, funded by Boehringer Ingelheim.
AstraZeneca and Ionis have received FDA approval for Waiuna, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR).
Irish pharmaceutical company Shorla Oncology and consultancy firm Eversana have announced the U.S. launch of JYLAMVO, the first oral methotrexate solution.
Gilda D’Incerti is CEO and founder of PQE Group, a life science consulting company, and she likes her company to work like a small English village where everyone knows each other.
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers, shakers and key announcements in the pharma industry. From Stand Up To Cancer, Astraveus and KBI Biopharma, we break down the key changes.
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence.
Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal...
Candel Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead adenovirus asset CAN-2409, for the treatment of pancreatic cancer.
Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.
ViroCell Biologics, a London-based viral vector CDMO for cell and gene therapy clinical trials, has partnered with University College London (UCL) to advance its pediatric cancer treatment.
Skye Bioscience has announced its plans to develop nimacimab, the company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity.
Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation to support its vaccine development efforts.
CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China's National Medical Products Administration (NMPA) for Yuanruida, a domestic CD19-targeting CAR-T therapy for relapsed/refractory B-Cell Acute Lymphocytic Leukemia.
Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a £1 million investment.
We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the...
London-based sustainable technologies company Johnson Matthey has partnered with biotechnology firm Basecamp Research to adopt more sustainable, bio-based catalysts.
GSK CEO Emma Walmsley has told Reuters that the company’s respiratory syncytial virus (RSV) vaccine is expected to make over $1.26 billion in its first year on the market.
Mytos, a London-based automated cell manufacturing company, has closed $19 million in Series A financing led by Buckley Ventures, with participation from IQ Capital and Wing VC.
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
Sanofi is planning to expand the market for its best-selling anti-inflammatory drug Dupixent, used to treat COPD, also known as ‘smokers lung’, after a successful second phase 3 trial.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
